1
|
Daiki K, Kanada Y, Nagata A, Nakamura S, Kato Y. Abstract P4-05-12: Kinetics of endocan in the peripheral blood before and after the resection of primary breast tumors. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p4-05-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: This study aims to investigate whether endocan levels in the peripheral blood change after the removal of primary breast tumors and allow predicting postoperative prognosis for breast cancer. Significance: An early prediction of postoperative recurrence and metastases with liquid biopsy will lead to better management and quality of life of breast cancer patients. Background: Cancer recurrence comes down to a poor prognosis in breast cancer patients. Although removal of primary breast cancer can achieve a successful outcome, metastasis and local recurrence remain a critical clinical problem in later years. Although the overall survival of breast cancer patients varies among molecular subtypes, the individual patients have different prognostic outcomes; some patients relapse within a few months, and others have not seen any recurrence for several years. Our previous study indicated that endocan had the potential to be a prognostic biomarker for triple-negative breast cancer. It is critical to show changes in endocan levels in the peripheral blood after the surgical excision of the primary tumor, which, in turn, will corroborate our hypothesis that plasma endocan is a beneficial biomarker for a postoperative prognosis for breast cancer patients. We included all the breast cancer subtypes in this study as the information on endocan levels in the peripheral blood from breast cancer patients has been limited thus far. Methods: To detect metastatic recurrence of breast cancer cells noninvasively, MDA-MB-231BR was transfected with the mVenus-Akaluc gene. MDA-MB-231BR spontaneously overexpresses the ESM1 gene. MDA-MB-231BR/mVenus-Akaluc was inoculated into the mammary fat pad of female athymic nu/nu mice and NSG mice. Once tumors top 200 mm3, they were surgically removed. Metastatic recurrence was visualized by the IVIS imager. Blood was withdrawn from the tail of each mouse before and after the resection of the primary tumors in a timely manner, and plasma samples were stored at -80°C until usage. Endocan in plasma samples was quantitated with a commercial ELISA kit. Tumor burden was estimated from luminescence signals of images obtained by IVIS. We obtained IRB approval from both institutions for the following research. Blood samples were collected from breast cancer patients who had given informed consent at the Breast Cancer, Showa University Hospital, and the plasma samples have been stored at -80°C until usage. Endocan in plasma sample was determined with a commercial ELISA kit. Results and discussion: Before removing primary breast tumors, the median endocan level in plasma was 0.73 ng/mL (range, 0.38-1.54 ng/mL) in nude mice. After the removal, endocan remained below the detection limits even though small metastases were detected by IVIS imager at later time points. These data indicate that loss of primary tumors results in an out-of-detection range in endocan levels in the blood. In contrast, NSG mice displayed inconsistent results: out of eight mice, three mice showed a decrease in endocan, three had an increase in endocan, and two had no change three days postoperatively. IVIS images of NSG mice indicated that distant metastases were already detected even when some mice underwent tumor resection. In NSG mice, the occurrence of tumor metastases was much earlier, and metastatic tumor burdens were much more significant than in nude mice, which might lead to a different outcome. Endocan levels in plasma from breast cancer patients at the postoperative period were not always dropped, which was similar to the results obtained from NSG mice. The rationale behind the inconsistent kinetics of endocan remains to be clarified. Conclusion: Our results from NSG mice and clinical data in patients’ plasma may have more relevance to prognostic outcomes in breast cancer patients.
Citation Format: Kentaro Daiki, Yoko Kanada, Aya Nagata, Seigo Nakamura, Yoshinori Kato. Kinetics of endocan in the peripheral blood before and after the resection of primary breast tumors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-12.
Collapse
Affiliation(s)
- Kentaro Daiki
- Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan
| | | | - Aya Nagata
- Showa University School of Medicine, Tokyo, Japan
| | | | - Yoshinori Kato
- Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan
| |
Collapse
|
2
|
Tsuchida Y, Ohde S, Nakamura R, Kanada Y, Miura S, Takimoto M, Nakamura S, Kanomata N, Yamauchi H, Hayashi N. A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
532 Background: In the prospective TAILORx and RxPONDER trials, the 21-gene Recurrence Score (RS) showed endocrine therapy alone was non-inferior to chemo-endocrine therapy in the analysis of invasive disease-free survival in postmenopausal hormone-receptor (HR)-positive breast cancer patients with RS < = 25. They also indicated chemotherapy was associated with benefit for women 50 years or younger with RS 11 to 25. However, in Japan, the test is not conventionally available because of non-coverage by national insurance. We aimed to develop and validate a model to predict RS using clinicopathological factors that identify patients who would have low risk shown by testing the 21-gene RS and can avoid chemotherapy. Methods: Four hundred patients, including 187 N0/1 postmenopausal, and 213 N0 premenopausal women who underwent surgery and had the RS from St. Luke’s International Hospital, Tokyo, Japan, were included in derivation cohort. Derivation cohort was divided into 2 groups by RS 25; patients with RS of 0 to 25 (n = 321) and with RS over 26 (n = 79). Multivariate logistic regression analysis was performed using candidate factors for all patients and pre- or postmenopausal patients. The prediction model was validated using an external cohort of 70 patients from Showa University School of Medicine, Tokyo, Japan. Results: Nuclear grade (NG) (adjusted OR, 5.28, 95% CI, 2.47–11.30), high Progesterone receptor (PgR) expression (Allred score 7-8) (adjusted OR, 10.62, 95% CI, 5.34–21.13) and low Ki67 level ( < = 20%) (adjusted OR, 5.29, 95% CI, 2.33-12.01) were significant independent predictors of RS of 0 to 25. With these factors could predict RS of 0 to 25 (AUC of 0.848, 95% CI, 0.803-0.893) with the highest probability of low-RS for 100%. The prediction model of the validation cohort had same discriminatory ability having an AUC of 0.812 (95% CI, 0.701-0.923). In postmenopausal patients, NG (adjusted OR, 4.81, 95% CI, 1.72–13.42), high PgR expression (adjusted OR, 10.62, 95% CI, 4.52–37.72), and low Ki67 level (adjusted OR, 4.94, 95%CI, 1.87-13.04) were significantly associated with RS of 0 to 25 in multivariate analysis. A regression model with these 4 factors could predict RS of 0 to 25 (AUC of 0.842, 95%CI, 0.782-0.902). In premenopausal patients, NG (adjusted OR, 8.76, 95% CI, 1.14–67.40), high PgR expression (adjusted OR, 3.22, 95% CI, 1.61–6.43), and low Ki67 level (adjusted OR, 2.87, 95% CI, 1.20–6.87) were significantly associated with RS of 0 to 10 in multivariate analysis. These factors could predict RS of 0 to 10 (AUC of 0.811, 95% CI, 0.731-0.891). However, the highest probability of low-RS provided this model for premenopausal women was 46.8%. Conclusions: Our validated model could provide useful information to distinguish low-RS especially for postmenopausal patients with high reproducibility. However, for premenopausal women, the 21-gene RS is warranted.
Collapse
Affiliation(s)
- Yasue Tsuchida
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
| | - Sachiko Ohde
- Center for Clinical Epidemiology and Health Technology Assessment, St. Luke's International University, and Graduate School of Public Health, St. Luke's International University, Tokyo, Japan
| | - Ryota Nakamura
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
| | - Yoko Kanada
- Department of Surgery, Japan Labour Health and Safety Organization, Tokyo Rosai Hospital, Tokyo, Japan
| | - Sakiko Miura
- Department of Pathology, Showa University, School of Medicine, Tokyo, Japan
| | - Masafumi Takimoto
- Department of Pathology, Showa University School of Medicine, Tokyo, Japan
| | - Seigo Nakamura
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Naoki Kanomata
- Department of Pathology, St. Luke's International Hospital, Tokyo, Japan
| | - Hideko Yamauchi
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
| | - Naoki Hayashi
- Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan
| |
Collapse
|
3
|
Kurita T, Taruno K, Nakamura S, Takei H, Enokido K, Kuwayama T, Kanada Y, Akashi S, Nakai M, Hankyo M, Yanagihara K, Sakatani T, Sakamaki K, Kuwahata A, Sekino M, Kusakabe M. Abstract P1-20-17: Magnetic guided localization for non-palpable breast lesion: A multi-center open-label trial in Japan. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p1-20-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Non-palpable breast lesions represent about 25-35% of all breast cancers diagnosed in developed countries, according to findings based on the evolution of imaging modalities such as MRI, and the uses reliable biopsy techniques such as ultrasound-guided or stereo-guided vacuum assisted biopsy. Wire -guided localization (WGL), radio-guided localization (RGL), and SAVI SCOUT localization (SSL) have been presented as a surgical procedure for non-palpable breast lesion. The reported disadvantages of WGL are related to mechanical stimulation of wire plucking, kinking, and patient discomfort. RGL has issues regarding radioactive licensing, handling, and waste management, and the SSL system requires high start-up costs. To eliminate these problems, we verified the magnetically guided localization (MGL) method for breast lesion localization by means of the combinations of the magnetic probe TAKUMI (ISO13485, Matrix cell Research Institute Inc., Tokyo, Japan) and the guiding-marker system® (Hakko, Tokyo, JAPAN). The TAKUMI is a novel handheld magnetic probe with a permanent magnet and a Hall magnetic sensor for detecting magnetic substances. It was newly developed at the University of Tokyo under a grant from the Japan Agency for Medical Research and Development (AMED). The aim of this study was to evaluate the feasibility and safety of our MGL system. Method: Patients were enrolled in this multi-center, open-label trial from January 2019 to March 2019 at two University Hospitals. The inclusion criteria were age 20 or older female patients who had non-palpable breast lesions, for which breast-conserving surgery or tumor resection was performed. Patients who had a metal allergy, pregnancy, or inflammatory breast cancer were excluded. The guiding-marker system® consists of a stainless-steel hook (φ 0.28 × 10 mm) connected with a nylon thread and an a 21-gauge 10 cm long steel needle.The marker was inserted into the center of the target lesions using ultrasound guidance or stereo guidance within 4 days before surgery. The TAKUMI was used to determine whether the guiding marker was detectable or not before, during, and after the surgical resection of the specimen. The resection rate of the guiding marker, surgical margin status, and re-operation rates were evaluated as the primary outcomes, and the volume and weight of the excised specimen were evaluated as secondary outcomes. The study protocol of the evaluation of magnetic probe system for detecting of non-palpable lesions of the breast was approved by the Institutional Review Board of Nippon Medical School Foundation (CRB3180001) and was registered at https://jrct.niph.go.jp/re (protocol record jRCTs032180422). Written informed consent was obtained from all participants. Results: Forty-one patients were recruited into this study. Thirty-eight patients (92.6%) underwent breast-conserving surgery for breast cancer treatment, and 3 (7.3%) underwent tumor resection for biopsy purposes. All guiding markers were resected during the initial surgical operation. Three out of 38 breast cancer patients (7.9%) were diagnosed as margin positive in frozen section analysis; 2 (5.2%) underwent additional resection during the initial surgery due to the positive margin, and 1 (2.6%) underwent subsequent surgery due to the positive margin on final pathology. Eight patients (21%) underwent boost radiation therapy due to the close margin (<5mm). The median excised specimen weight was 28 g. The range was wide (2-131 g) and depended on the expanse of the lesion. No complications or adverse events were recorded in relation to either the marker placement or the surgery. Conclusion: These data clearly show that MGL is a reliable, accurate, and convenient localization system for non-palpable breast lesions. It is able to eliminate the disadvantages of WGL, RGL, and SSL.
Citation Format: Tomoko Kurita, Kanae Taruno, Seigo Nakamura, Hiroyuki Takei, Katsutoshi Enokido, Takashi Kuwayama, Yoko Kanada, Sadako Akashi, Maki Nakai, Meishi Hankyo, Keiko Yanagihara, Takashi Sakatani, Kentaro Sakamaki, Akihiko Kuwahata, Masaki Sekino, Moriaki Kusakabe. Magnetic guided localization for non-palpable breast lesion: A multi-center open-label trial in Japan [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-20-17.
Collapse
Affiliation(s)
- Tomoko Kurita
- 1Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Kanae Taruno
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Seigo Nakamura
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Hiroyuki Takei
- 1Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Katsutoshi Enokido
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Takashi Kuwayama
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Yoko Kanada
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Sadako Akashi
- 2Department of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan
| | - Maki Nakai
- 1Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Meishi Hankyo
- 1Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Keiko Yanagihara
- 1Department of Breast Surgery and Oncology, Nippon Medical School Hospital, Tokyo, Japan
| | - Takashi Sakatani
- 3Department of Pathology, Nippon Medical School Hospital, Tokyo, Japan
| | - Kentaro Sakamaki
- 4Center for Data Science, Yokohama City University, Yokohama, Japan
| | - Akihiko Kuwahata
- 5The Graduate School of Engineering, University of Tokyo, Tokyo, Japan
| | - Masaki Sekino
- 5The Graduate School of Engineering, University of Tokyo, Tokyo, Japan
| | | |
Collapse
|
4
|
Liu Y, Ide Y, Inuzuka M, Tazawa S, Kanada Y, Matsunaga Y, Kuwayama T, Sawada T, Akashi-Tanaka S, Nakamura S. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ. Mol Genet Genomic Med 2019; 7:e493. [PMID: 30652428 PMCID: PMC6418441 DOI: 10.1002/mgg3.493] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 08/26/2018] [Accepted: 10/02/2018] [Indexed: 12/21/2022] Open
Abstract
Background Ductal carcinoma in situ (DCIS) is considered a component of the clinical spectrum of breast cancer even in those with BRCA1/2 mutation. The aim of this study was to report the feature of DCIS raised in Japanese women with BRCA1/2 mutations. Methods A total of 325 Japanese women with breast cancer (BC) (with or without invasive cancer) were referred for genetic counseling and underwent genetic testing for mutations in the BRCA1 and BRCA2 genes in Showa University Hospital between December 2011 and August 2016. And 49 of them who were pathologically diagnosed as DCIS were included in this study. Logistic regression models were fit to determine the associations between potential predictive factors and BRCA status. A Cox proportional hazards model is used to predictive value of parameters for Ipsilateral breast tumor recurrence (IBTR) and contralateral breast tumor recurrence (CBTR). Results (a) Of 325 patients (with or without invasive cancer), 19.1% (62/325) tested positive for BRCA1/BRCA2 mutations. And 18.4% (9/49) was positive for BRCA1/BRCA2 mutations in DCIS, compared with 19.2% (53/276) in IDC (p = 1.000). Among BRCA mutations, 14.5% (9/62) had DCIS compared with nonmutations (15.2%, 40/263). Incidence of DCIS was 3.0% (1/33) of BRCA1 mutations and 27.5% (8/29) of BRCA2 mutation (p = 0.009). (b) Median age of diagnosis in BRCA mutation carriers was 39 years, compared with 46 years in noncarriers. Age, Family history (FH) of BC, FH of first or second BC and total number of relatives with BC diagnosis (DX) has significant difference between BRCA mutation carriers and noncarriers in univariate analysis. In a multivariate logistic model, total relatives with BC DX ≥ 2 (odds ratio [OR], 5.128; 95% confidence interval [CI], 1.266–20.763; p = 0.022), age at diagnosis ≤35 years (OR 0.149, 95% CI 0.023–0.954, p = 0.045) and ER+/HER2+ status (OR 5.034, 95% CI 1.092–23.210, p = 0.038) remained as independent significant predictors for BRCA mutation. Ki67 index (cut off by 14% or 30%) did not differ between BRCA mutation carriers and noncarriers (p = 0.459 and p = 0.651). (c) There was a significant difference in ER‐positive tumors among BRCA2 carriers and noncarriers (p = 0.042). Subgroup analysis showed BRCA2 carriers tend to be of higher grade (Grade 2 and 3), more frequently ER+/PR+ (p = 0.041) and lower proliferation (Ki67 index) than noncarriers, whereas differences in nuclear grade and ki67 index were not found significantly in our study. (d) BRCA mutation was not associated with an increased risk of IBTR and CBTR. Conclusion DCIS is equally as prevalent in patients who were BRCA mutation carriers as in high familial‐risk women who were noncarriers, but occurs at earlier age. BRCA2 carriers have higher incidence in DCIS than that of BRCA1 carriers, and tend to be higher grade and more frequently ER positive and lower proliferation. Total relatives with BC DX ≥2, age at diagnosis ≤35 years and ER+/HER2+ might be independent predictors for BRCA mutation in Japanese women with DCIS and patients of these risk factors should be recommended to receive genetic counseling and BRCA testing.
Collapse
Affiliation(s)
- Yan Liu
- The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.,Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China.,Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.,Tianjin's Clinical Research Center for Cancer, Tianjin, China.,Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Yoshimi Ide
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Mayuko Inuzuka
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Sakiko Tazawa
- Department of Pathology, Showa University Hospital, Tokyo, Japan
| | - Yoko Kanada
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Yuki Matsunaga
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Takashi Kuwayama
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Terumasa Sawada
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Sadako Akashi-Tanaka
- Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| | - Seigo Nakamura
- The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.,Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, China.,Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.,Tianjin's Clinical Research Center for Cancer, Tianjin, China.,Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Tsuchida Y, Hayashi N, Omata F, Ohde S, Kanada Y, Tazawa S, Takimoto M, Suzuki K, Nakamura S, Yamauchi H. Prediction model of low risk recurrence distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer: A validation study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx655.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Sazuka T, Matsuzaki H, Kanada Y, Tohnosu N, Yoshiwara C, Aruga T, Iwata K, Sasahara N, Kobayashi H, Yokoyama M, Otsuka R, Yanagihara A, Yoshioka T, Maruyama T, Matsubara H. [A Case of Malignant Phyllodes Tumor Effectively Treated by Radiation Therapy as a Palliative Medicine]. Gan To Kagaku Ryoho 2015; 42:1698-1699. [PMID: 26805142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The current report presents the case of a 46-year-old woman with phyllodes tumor metastasis to the anterior chest wall treated by radiation therapy. Although the lesion was not controlled with surgery and chemotherapy, the tumor size markedly reduced after radiation therapy, and bleeding and foul odor from the tumor stopped. Radiation therapy for phyllodes tumor appears to be an effective treatment and should be recognized as one choice of palliative medicine.
Collapse
|
7
|
Note H, Shimizu S, Ariga T, Suzuki K, Kobayashi H, Sawada N, Kanada Y, Senba Y, Yoshioka T, Sato Y, Miyazaki A, Natsume T, Matsuzaki H, Tanaka H, Maruyama T. [A Case of Pathologically Complete Response of a Rectal Cancer after Preoperative Treatment with mFOLFOX6 and Radiation Therapy]. Gan To Kagaku Ryoho 2015; 42:1472-1474. [PMID: 26805067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
A 60-year-old man who had bloody stools after sigmoid colonoscopy was admitted to our hospital. A digital examination and sigmoid colonoscopy showed a type 2 circular tumor at location Rb with incomplete mobility and tumor hemorrhage, and the result of a biopsy was moderately differentiated adenocarcinoma (tub2). Computed tomography and magnetic resonance imaging suggested a possibility of invasion of the primary rectal tumor to the sacrum. The clinical stage was cT4bN0M0H0P0, cStage Ⅱ, which is generally not treatable by surgery. Sigmoid colostomy was performed, and a central venous port was implanted. After a preoperative treatment consisting of 3 courses of mFOLFOX6 and radiation therapy, the clinical stage changed to ycT2N0M0H0P0, ycStageⅠ. Super-low anterior resection and covering ileostomy were performed 46 days after the preoperative treatment. A pathological examination revealed no residual cancer cells in the primary lesion and lymph node (Grade 3, pCR). The patient has been disease-free for 4 years and 9 months after the operation.
Collapse
Affiliation(s)
- Hiromasa Note
- Dept. of Surgery, Funabashi Municipal Medical Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Kanada Y, Matsuzaki H, Kobayashi H, Suzuki K, Sawada H, Senba Y, Yoshioka T, Note H, Sato Y, Miyazaki A, Natsume T, Tanaka H, Maruyama T. [A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy]. Gan To Kagaku Ryoho 2015; 42:1509-1511. [PMID: 26805079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The patient was a 39-year-old woman who was referred to our hospital with suspicion of locally-advanced breast cancer. After several tests, she received a diagnosis of cT4bN1M1 (liver), Stage Ⅳbreast cancer. The liver metastasis was located in S4, and was 1 cm in size. Core needle biopsy was performed on the breast tumor; the pathological diagnosis was invasive ductal carcinoma (scirrhous carcinoma), nuclear Grade (NG) 3, and HER2-positive. She received epirubicin plus cyclophosphamide (EC) followed by docetaxel (DOC) plus pertuzumab (PER) plus trastuzumab (HER). After chemotherapy, the liver metastasis and axillary lymph node metastases had disappeared on imaging findings, showing a complete response (CR), but the primary breast tumor remained, showing a partial response (PR). She underwent mastectomy and axillary lymph node dissection for local control. After surgery, no metastases including liver metastases were seen on CT. The patient is currently receiving tamoxifen and anti-HER2 therapy.
Collapse
Affiliation(s)
- Yoko Kanada
- Dept. of Surgery, Funabashi Municipal Medical Center
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Iwata K, Yamazaki T, Kimura K, Sugiura T, Shirai M, Nakai T, Sakurai H, Kanada Y. Key to the independence of patients with severe stroke-related hemiplegia in toileting—focusing on lower body dressing. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.3503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
10
|
Yamamoto Y, Tanaka H, Maruyama T, Matsuzaki H, Natsume T, Miyazaki A, Satoh Y, Satsuka T, Yoshioka T, Kanada Y, Otsuka R, Yanagihara A, Yokoyama M, Kobayashi T. [Long-term survival of a patient with esophageal cancer with brain metastasis after multidisciplinary therapy - a case report]. Gan To Kagaku Ryoho 2014; 41:2006-2009. [PMID: 25731404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A 70-year-old woman was admitted for difficulty in swallowing. Esophageal cancer (MtLt, type 3, T4N3M0, cStage IVa) was diagnosed in May 2010. The cancer was unresectable, and chemoradiotherapy (CRT) with TS-1 was initiated in June 2010, and a partial response (PR) was observed. After CRT, TS-1 was continued, but a brain metastasis was detected owing to the development of right hemiplegia in April 2012. Craniotomy and tumorectomy were performed, and the right hemiplegia improved. Pathological examination of the brain tumor indicated squamous cell carcinoma. Because of a recurrence of brain metastasis, a gamma knife procedure was performed in May 2012. Subsequently, several recurrences of brain metastases were diagnosed, and a total of 7 gamma knife procedures were performed up to January 2014. Although systemic chemotherapy (5-fluorouracil and cisplatin [FP], 5 courses)was administered, the patient showed progressive lung metastases in February 2013. The chemotherapy regimen was changed from FP to docetaxel (TXT), but the lung metastases continued to progress up to June 2013. The patient died in March 2014. Patients with esophageal cancer and metastases to the brain have poor prognosis, but the present patient survived approximately 2 years after first diagnosis of metastases to the brain after multidisciplinary therapy.
Collapse
Affiliation(s)
- Yuji Yamamoto
- Dept. of Surgery, Funabashi Municipal Medical Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Otsuka R, Maruyama T, Tanaka H, Matsuzaki H, Natsume T, Miyazaki A, Sato Y, Sazuka T, Yamamoto Y, Yoshioka T, Kanada Y, Yanagihara A, Yokoyama M, Kobayashi H, Shimizu S. [A case of adenosquamous carcinoma of the sigmoid colon with inferior mesenteric vein thrombosis]. Gan To Kagaku Ryoho 2014; 41:1663-1664. [PMID: 25731288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A 63-year-old man who had been admitted to another institute with sepsis and renal failure was referred to our hospital after computed tomography (CT) findings showed thickening of the walls in the sigmoid colon and a defect in contrast enhancement in the portal and inferior mesenteric veins. Emergency sigmoid colon resection with D2 lymphadenectomy was performed after detection of perforation due to sigmoid colon cancer. The histopathological diagnosis was adenosquamous carcinoma, pSS, int, INF b, ly1, v0, pN2, pStage IIIband inferior mesenteric vein thrombosis. He was discharged on day 12, and we administered anticoagulant warfarin therapy.
Collapse
Affiliation(s)
- Ryota Otsuka
- Dept. of Surgery, Funabashi Municipal Medical Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Yamamoto Y, Shimizu S, Maruyama T, Tanaka H, Matsuzaki H, Natsume T, Miyazaki A, Satoh Y, Satsuka T, Yoshioka T, Kanada Y, Otsuka R, Yanagihara A, Yokoyama M, Kobayashi T. [A case of sigmoid colon cancer with abdominal wall abscess]. Gan To Kagaku Ryoho 2014; 41:1779-1781. [PMID: 25731327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
A 63-year-old man was admitted for an abdominal mass. Computed tomography revealed an abscess (21 × 20 cm) in the abdominal wall and a tumor in the sigmoid colon. Thus, cancer of the sigmoid colon complicated by an abscess of the abdominal wall was diagnosed. The abscess was drained and transverse colostomy was performed with curative intent. After the intervention, chemotherapy (XELOX×3) was administered. Three months later, sigmoidectomy was performed and the stoma was closed. Macroscopic and microscopic examination of the resected specimen detected no remnants of cancer. In patients with advanced colon cancer and abdominal wall involvement, a two-stage operation and preoperative chemotherapy may be considered essential when curative resection is performed.
Collapse
Affiliation(s)
- Yuji Yamamoto
- Dept. of Surgery, Funabashi Municipal Medical Center
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Tanabe S, Kubota S, Itoh N, Kimura T, Muraoka Y, Shimizu A, Kanada Y. Estimation of the kinetic-optimized stimulus intensity envelope for drop foot gait rehabilitation. J Med Eng Technol 2012; 36:210-6. [DOI: 10.3109/03091902.2012.666320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
14
|
Ohta K, Murata K, Takahashi T, Minatani S, Sako S, Kanada Y. Evaluation of swallowing function by two screening tests in primary COPD. Eur Respir J 2009; 34:280-1. [PMID: 19567612 DOI: 10.1183/09031936.00016909] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
Wataya-Kanada M, Kanada Y, Yoshikawa K. 186 Identification and analysis of 40 kDa protein lost in tuberous sclerosis. J Dermatol Sci 1997. [DOI: 10.1016/s0923-1811(97)81884-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Abstract
Glycated hemoglobin, considered to be the best index for the treatment of diabetes mellitus, was measured by electrospray ionization mass spectrometry (ESI/MS) according to the method proposed by Morris et al. at the 44th ASMS Conference on Mass Spectrometry and Allied Topics, 1996. They compared the values obtained by MS and affinity chromatography. Here, the values obtained by ESI/MS were compared with those obtained by high-performance liquid chromatography and by latex agglutination immunoassay. Whole blood samples were diluted 500 fold with 0.2% formic acid-50% acetonitrile solution and 5 microliters of the diluted solution was injected with the ESI/MS system (TSQ 7000) via a sample loop. The within-run and between-run relative standard deviations of the ratio of glycated and non-glycated beta-chain were less than 5%. The correlation coefficients between ESI/MS and conventional methods were higher than 0.96. However, considerable discrepancies were observed among methods. ESI/MS will allow reproducible measurements of glycated hemoglobin and will be useful in the quality control of HbA1c measurement by other principles and also in routine clinical laboratory tests.
Collapse
Affiliation(s)
- T Nakanishi
- Department of Clinical Pathology, Osaka Medical College, Japan
| | | | | | | | | | | | | |
Collapse
|
17
|
|